Sompharmaceuticals is a Swiss biopharmaceutical company founded in 2012 and based at the Biopôle in Epalinges-Lausanne, Switzerland. The company's mission is to develop innovative anti-tumor somatostatin analogue (SSA) peptide medicines and diagnostics for patients with rare endocrine and neuroendocrine tumors, addressing unmet medical needs. These conditions include growth hormone-producing pituitary brain tumors (acromegaly) and malignant neuroendocrine hormone-producing intestinal and pancreatic tumors (NETs) that are not effectively treated by existing SSA medications, such as octreotide and lanreotide.
Sompharmaceuticals operates in the Biotechnology, Health and Wellness, and Pharmaceutical sectors, targeting significant market opportunities within the rare disease treatment landscape. The company received a Fr.750.00K Series A investment on April 29, 2014.
The firm's slogan, "Pioneering new therapies for rare endocrine and neuroendocrine tumors with unmet medical needs," succinctly captures its dedication to innovation in addressing challenging medical conditions. With its focus on developing novel therapies and diagnostics, Sompharmaceuticals presents an intriguing opportunity for venture capital investment in the biopharmaceutical space.
